Cargando…
Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus
Cache Valley virus (CVV) is a mosquito-borne bunyavirus that is enzootic throughout the new world. Although CVV is known as an important agricultural pathogen, primarily associated with embryonic lethality and abortions in ruminants, it has recently been recognized for its expansion as a zoonotic pa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885547/ https://www.ncbi.nlm.nih.gov/pubmed/36622942 http://dx.doi.org/10.1089/vim.2022.0103 |
_version_ | 1784879951265136640 |
---|---|
author | Ayers, Victoria B. Huang, Yan-Jang S. Kohl, Alain Dunlop, James I. Hettenbach, Susan M. Park, So Lee Higgs, Stephen Vanlandingham, Dana L. |
author_facet | Ayers, Victoria B. Huang, Yan-Jang S. Kohl, Alain Dunlop, James I. Hettenbach, Susan M. Park, So Lee Higgs, Stephen Vanlandingham, Dana L. |
author_sort | Ayers, Victoria B. |
collection | PubMed |
description | Cache Valley virus (CVV) is a mosquito-borne bunyavirus that is enzootic throughout the new world. Although CVV is known as an important agricultural pathogen, primarily associated with embryonic lethality and abortions in ruminants, it has recently been recognized for its expansion as a zoonotic pathogen. With the increased emergence of bunyaviruses with human and veterinary importance, there have been significant efforts dedicated to the development of bunyavirus vaccines. In this study, the immunogenicity of a candidate live-attenuated vaccine (LAV) for CVV, which contains the deletion of the nonstructural small (NSs) and nonstructural medium (NSm) genes (2delCVV), was evaluated and compared with an autogenous candidate vaccine created through the inactivation of CVV using binary ethylenimine (BEI) with an aluminum hydroxide adjuvant (BEI-CVV) in sheep. Both 2delCVV and BEI-CVV produced a neutralizing antibody response that exceeds the correlate of protection, that is, plaque reduction neutralization test titer >10. However, on day 63 postinitial immunization, 2delCVV was more immunogenic than BEI-CVV. These results warrant further development of 2delCVV as a candidate LAV and demonstrate that the double deletion of the NSs and NSm genes can be applied to the development of vaccines and as a common attenuation strategy for orthobunyaviruses. |
format | Online Article Text |
id | pubmed-9885547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-98855472023-02-01 Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus Ayers, Victoria B. Huang, Yan-Jang S. Kohl, Alain Dunlop, James I. Hettenbach, Susan M. Park, So Lee Higgs, Stephen Vanlandingham, Dana L. Viral Immunol Original Articles Cache Valley virus (CVV) is a mosquito-borne bunyavirus that is enzootic throughout the new world. Although CVV is known as an important agricultural pathogen, primarily associated with embryonic lethality and abortions in ruminants, it has recently been recognized for its expansion as a zoonotic pathogen. With the increased emergence of bunyaviruses with human and veterinary importance, there have been significant efforts dedicated to the development of bunyavirus vaccines. In this study, the immunogenicity of a candidate live-attenuated vaccine (LAV) for CVV, which contains the deletion of the nonstructural small (NSs) and nonstructural medium (NSm) genes (2delCVV), was evaluated and compared with an autogenous candidate vaccine created through the inactivation of CVV using binary ethylenimine (BEI) with an aluminum hydroxide adjuvant (BEI-CVV) in sheep. Both 2delCVV and BEI-CVV produced a neutralizing antibody response that exceeds the correlate of protection, that is, plaque reduction neutralization test titer >10. However, on day 63 postinitial immunization, 2delCVV was more immunogenic than BEI-CVV. These results warrant further development of 2delCVV as a candidate LAV and demonstrate that the double deletion of the NSs and NSm genes can be applied to the development of vaccines and as a common attenuation strategy for orthobunyaviruses. Mary Ann Liebert, Inc., publishers 2023-01-01 2023-01-16 /pmc/articles/PMC9885547/ /pubmed/36622942 http://dx.doi.org/10.1089/vim.2022.0103 Text en © Victoria B. Ayers et al. 2023; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ayers, Victoria B. Huang, Yan-Jang S. Kohl, Alain Dunlop, James I. Hettenbach, Susan M. Park, So Lee Higgs, Stephen Vanlandingham, Dana L. Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus |
title | Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus |
title_full | Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus |
title_fullStr | Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus |
title_full_unstemmed | Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus |
title_short | Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus |
title_sort | comparison of immunogenicity between a candidate live attenuated vaccine and an inactivated vaccine for cache valley virus |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885547/ https://www.ncbi.nlm.nih.gov/pubmed/36622942 http://dx.doi.org/10.1089/vim.2022.0103 |
work_keys_str_mv | AT ayersvictoriab comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT huangyanjangs comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT kohlalain comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT dunlopjamesi comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT hettenbachsusanm comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT parksolee comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT higgsstephen comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus AT vanlandinghamdanal comparisonofimmunogenicitybetweenacandidateliveattenuatedvaccineandaninactivatedvaccineforcachevalleyvirus |